CellCarta Executive and Leadership Team

Dusty Tenney, the Chief Executive Officer at CellCarta, directs the overarching corporate strategy and operational execution. Tenney guides the organization's mission to provide comprehensive biomarker platforms and services, essential for advancing precision medicine within the biopharmaceutical industry. This leadership role involves fostering strategic partnerships and ensuring the company's continued growth and market leadership in complex scientific testing solutions. The Chief Executive Officer's focus remains on addressing the most intricate scientific challenges faced by clients, thereby unlocking the full potential of personalized therapeutic approaches. Dusty Tenney's strategic vision propels CellCarta's commitment to delivering customized biomarker testing solutions that meet the evolving demands of global healthcare research and development. The Chief Executive Officer's influence extends to shaping the company's long-term objectives and reinforcing its position as a premier Contract Research Organization Laboratory (CRO).

Elliott Miller, the Chief Financial Officer at CellCarta, manages all financial operations and fiscal strategy. Miller oversees budgeting, financial planning, and resource allocation to support the company's expansion as a global Contract Research Organization Laboratory (CRO). This executive ensures robust financial health, enabling CellCarta to invest in cutting-edge biomarker platforms and services. The Chief Financial Officer's responsibilities include optimizing financial performance and driving profitability, crucial for sustaining the delivery of customized biomarker testing solutions. Elliott Miller's financial acumen is vital for navigating the complexities of the biopharmaceutical industry and supporting the advancement of precision medicine. The Chief Financial Officer's role involves close collaboration with other C-suite leaders to align financial objectives with the company's scientific and market goals, ensuring sustainable growth and operational excellence.

Anthony Mattacchione, the Global Chief Financial Officer at CellCarta, directs worldwide financial planning, reporting, and fiscal management. Mattacchione ensures financial compliance and optimizes capital deployment across CellCarta's international operations as a Contract Research Organization Laboratory (CRO). This executive's purview includes managing global financial risks and identifying opportunities for strategic investment in biomarker platforms and services. The Global Chief Financial Officer's role is pivotal in supporting the company's mission to deliver customized biomarker testing solutions that drive precision medicine forward. Anthony Mattacchione's financial leadership is critical for sustaining CellCarta's capacity to address the most complex scientific testing needs on a global scale. The Global Chief Financial Officer's oversight guarantees financial stability and supports the company's ambitious growth objectives in the biopharmaceutical research sector.

Louis Norton, the Chief Information Officer at CellCarta, architects and oversees the company's entire information technology infrastructure and digital strategy. Norton ensures the secure and efficient management of data critical to biomarker discovery and analysis, supporting CellCarta's role as a leading CRO. This leadership position involves implementing advanced technological solutions that enhance operational efficiency and data integrity for biopharmaceutical clients. The Chief Information Officer's focus is on leveraging technology to streamline complex scientific testing processes and facilitate the development of precision medicine. Louis Norton's expertise is essential for maintaining a competitive edge in data-driven research, ensuring that CellCarta's IT systems effectively support its broad offering of biomarker platforms and services. The Chief Information Officer's strategic direction ensures technological alignment with the company's mission to address the most complex scientific testing needs.

Ehab ElGabry, the Chief Medical Officer at CellCarta, provides critical medical and scientific leadership for the company's biomarker services. ElGabry guides the strategic direction of clinical research initiatives, ensuring CellCarta's offerings align with the evolving needs of the biopharmaceutical industry and the advancement of precision medicine. This role involves translating complex scientific findings into actionable insights for clients, enhancing the value of customized biomarker testing solutions. The Chief Medical Officer's expertise is fundamental to addressing the most challenging scientific testing needs and reinforcing CellCarta's position as a premier CRO. Ehab ElGabry's medical insights are instrumental in shaping the company's research and development efforts, particularly in areas requiring deep clinical understanding. The Chief Medical Officer's leadership ensures that CellCarta remains at the forefront of scientific innovation in biomarker discovery and application.